Nature and nurture of catalytic antibodies

Advances in Experimental Medicine and Biology

Volumn 750, Issue , 2012, Pages 56-75

  Paul, Sudhir ^a,b   Planque, Stephanie A ^a   Nishiyama, Yasuhiro ^a   Hanson, Carl V ^c   Massey, Richard J ^b  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^b Covalent Bioscience Inc ^*  (United States)

^c VIRAL AND RICKETTSIAL DISEASE LABORATORY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; CATALYTIC ANTIBODY; EPITOPE; GLYCOPROTEIN GP 120; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN HEAVY CHAIN; IMMUNOGLOBULIN LIGHT CHAIN; IMMUNOGLOBULIN M; LYMPHOCYTE ANTIGEN RECEPTOR; SUPERANTIGEN;

ADAPTIVE IMMUNITY; ALZHEIMER DISEASE; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; ANTIBODY STRUCTURE; ANTIGEN ANTIBODY COMPLEX; ANTIGEN BINDING; ANTIGEN EXPRESSION; ANTIGEN RECOGNITION; ARTICLE; AUTOIMMUNITY; BINDING SITE; COMPLEMENTARITY DETERMINING REGION; CROSS REACTION; DOWN REGULATION; HELICOBACTER INFECTION; HOST RESISTANCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOTHERAPY; LIPID PEROXIDATION; MICROORGANISM; NONHUMAN; PHYLOGENY; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN DEGRADATION; VACCINATION; ANIMAL; B LYMPHOCYTE; CHEMISTRY; COMMUNICABLE DISEASE; IMMUNOGLOBULIN VARIABLE REGION; IMMUNOLOGY;

ANIMALS; ANTIBODIES, CATALYTIC; AUTOANTIBODIES; B-LYMPHOCYTES; COMMUNICABLE DISEASES; COMPLEMENTARITY DETERMINING REGIONS; HUMANS; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; IMMUNOGLOBULIN VARIABLE REGION; RECEPTORS, ANTIGEN, B-CELL; SUPERANTIGENS;

EID: 84866787491     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4614-3461-0_5     Document Type: Article

References (47)

1. Dooley H, Flajnik MF. Antibody repertoire development in cartilaginous fish. Dev Comp Immunol 2006; 30:43-56; PMID:16146649; http://dx.doi.org/10.1016/ j.dci.2005.06.022. (Pubitemid 41405787)
2. Schluter SF, Bernstein RM, Bernstein H et al. 'Big Bang' emergence of the combinatorial immune system. Dev Comp Immunol 1999; 23:107-11; PMID:10227478. (Pubitemid 29140857)
3. Casali P, Schettino EW. Structure and function of natural antibodies. Curr Top Microbiol Immunol 1996; 210:167-79; PMID:8565555. (Pubitemid 26024271)
4. Guilbert B, Dighiero G, Avrameas S. Naturally occurring antibodies against nine common antigens in human sera. I. Detection, isolation and characterization. J Immunol 1982; 128:2779-87; PMID:6176652.
5. Barbouche R, Forveille M, Fischer A et al. Spontaneous IgM autoantibody production in vitro by B lymphocytes of normal human neonates. Scand J Immunol 1992; 35:659-67; PMID:1376488; http:// dx.doi.org/10.1111/j.1365-3083.1992. tb02972.x.
6. Köhler F, Hug E, Eschbach C et al. Autoreactive B cell receptors mimic autonomous pre-B cell receptor signaling and induce proliferation of early B cells. Immunity 2008; 29:912-21; PMID:19084434; http:// dx.doi.org/10.1016/j. immuni.2008.10.013.
7. Tramontano A, Janda KD, Lerner RA. Catalytic antibodies. Science 1986; 234:1566-70; PMID:3787261; http://dx.doi.org/10.1126/science.3787261. (Pubitemid 17125281)
8. Paul S, Volle DJ, Beach CM et al. Catalytic hydrolysis of vasoactive intestinal peptide by human autoantibody. Science 1989; 244:1158-62; PMID:2727702; http://dx.doi.org/10.1126/science.2727702. (Pubitemid 19170484)
9. Shuster AM, Gololobov GV, Kvashuk OA et al. DNA hydrolyzing autoantibodies. Science 1992; 256:665-7; PMID:1585181; http://dx.doi.org/10. 1126/science.1585181.
10. Zhou GW, Guo J, Huang W et al. Crystal structure of a catalytic antibody with a serine protease active site. Science 1994; 265:1059-64; PMID:8066444; http://dx.doi.org/10.1126/science.8066444. (Pubitemid 24293072)
11. Nishiyama Y, Taguchi H, Luo JQ et al. Covalent reactivity of phosphonate monophenyl esters with serine proteinases: An overlooked feature of presumed transition state analogs. Arch Biochem Biophys 2002; 402:281-8; PMID:12051675; http://dx.doi.org/10.1016/S0003-9861(02)00087-5. (Pubitemid 34848648)
12. Avalle B, Thomas D, Friboulet A. Functional mimicry: Elicitation of a monoclonal anti-idiotypic antibody hydrolizing beta-lactams. FASEB J 1998; 12:1055-60; PMID:9707178. (Pubitemid 28359587)
13. Kohler H, Paul S. Superantibody activities: New players in innate and adaptive immune responses. Immunol Today 1998; 19:221-7; PMID:9613040; http://dx.doi.org/10.1016/S0167-5699(97)01234-6. (Pubitemid 28275574)
14. Paul S, Planque S, Zhou YX et al. Specific HIV gp120-cleaving antibodies induced by covalently reactive analog of gp120. J Biol Chem 2003; 278:20429-35; PMID:12665517; http://dx.doi.org/10.1074/jbc. M300870200. (Pubitemid 36799245)
15. Gao QS, Sun M, Rees AR et al. Site-directed mutagenesis of proteolytic antibody light chain. J Mol Biol 1995; 253:658-64; PMID:7473741; http://dx.doi.org/10.1006/jmbi.1995.0580.
16. Gololobov G, Sun M, Paul S. Innate antibody catalysis. Mol Immunol 1999; 36:1215-22; PMID:10684961; http://dx.doi.org/10.1016/S0161-5890(99)00141-8.
17. Sharma V, Heriot W, Trisler K et al. A human germ line antibody light chain with hydrolytic properties associated with multimerization status. J Biol Chem 2009; 284:33079-87; PMID:19801545; http://dx.doi. org/10.1074/jbc.M109. 036087.
18. Kalaga R, Li L, O'Dell JR et al. Unexpected presence of polyreactive catalytic antibodies in IgG from unimmunized donors and decreased levels in rheumatoid arthritis. J Immunol 1995; 155:2695-702; PMID:7650397.
19. Planque S, Bangale Y, Song XT et al. Ontogeny of proteolytic immunity: IgM serine proteases. J Biol Chem 2004; 279:14024-32; PMID:14726510; http://dx.doi.org/10.1074/jbc.M312152200. (Pubitemid 38468937)
20. Lacroix-Desmazes S, Bayry J, Kaveri SV et al. High levels of catalytic antibodies correlate with favorable outcome in sepsis. Proc Natl Acad Sci USA 2005; 102:4109-13; PMID:15743915; http://dx.doi. org/10.1073/pnas.0500586102. (Pubitemid 40388563)
21. Taguchi H, Planque S, Sapparapu G et al. Exceptional amyloid beta peptide hydrolyzing activity of nonphysiological immunoglobulin variable domain scaffolds. J Biol Chem 2008; 283:36724-33; PMID:18974093; http://dx.doi.org/10. 1074/jbc.M806766200.
22. Mitsuda Y, Planque S, Hara M et al. Naturally occurring catalytic antibodies: Evidence for preferred development of the catalytic function in IgA class antibodies. Mol Biotechnol 2007; 36:113-22; PMID:17914190; http://dx.doi.org/10.1007/s12033-007-0003-7. (Pubitemid 350135917)
23. Sun M, Li L, Gao QS et al. Antigen recognition by an antibody light chain. J Biol Chem 1994; 269:734-8; PMID:8276876. (Pubitemid 24026721)
24. Matsuura K, Yamamoto K, Sinohara H. Amidase activity of human Bence Jones proteins. Biochem Biophys Res Commun 1994; 204:57-62; PMID:7945392; http://dx.doi.org/10.1006/bbrc.1994.2425.
25. Paul S, Li L, Kalaga R et al. Natural catalytic antibodies: Peptide-hydrolyzing activities of Bence Jones proteins and VL fragment. J Biol Chem 1995; 270:15257-61; PMID:7797511; http://dx.doi.org/10.1074/ jbc.270.25.15257.
26. Matsuura K, Ohara K, Munakata H et al. Pathogenicity of catalytic antibodies: catalytic activity of Bence Jones proteins from myeloma patients with renal impairment can elicit cytotoxic effects. Biol Chem 2006; 387:543-8; PMID:16740125; http://dx.doi.org/10.1515/BC.2006.070. (Pubitemid 44071456)
27. Buneva VN, Kanyshkova TG, Vlassov AV et al. Catalytic DNA- and RNA-hydrolyzing antibodies from milk of healthy human mothers. Appl Biochem Biotechnol 1998; 75:63-76; PMID:10214697; http:// dx.doi.org/10.1007/BF02787709. (Pubitemid 29168619)
28. Li L, Paul S, Tyutyulkova S et al. Catalytic activity of anti-thyroglobulin antibodies. J Immunol 1995; 154:3328-32; PMID:7897215.
29. Thiagarajan P, Dannenbring R, Matsuura K et al. Monoclonal antibody light chain with prothrombinase activity. Biochemistry 2000; 39:6459-65; PMID:10828960; http://dx.doi.org/10.1021/bi992588w. (Pubitemid 30347151)
30. Yang YH, Chang CJ, Chuang YH et al. Identification of anti-prothrombin antibodies in the anti-phospholipid syndrome that display the prothrombinase activity. Rheumatology (Oxford) 2010; 49:34-42; PMID:19920091; http://dx.doi.org/10.1093/rheumatology/kep328.
31. Wootla B, Dasgupta S, Dimitrov JD et al. Factor VIII hydrolysis mediated by anti-factor VIII autoantibodies in acquired hemophilia. J Immunol 2008; 180:7714-20; PMID:18490775.
32. Wootla B, Christophe OD, Mahendra A et al. Proteolytic antibodies activate factor IX in patients with acquired hemophilia. Blood 2011; 117:2257-64; PMID:21131590; http://dx.doi.org/10.1182/blood-2010-07-296103.
33. Ponomarenko NA, Durova OM, Vorobiev II et al. Autoantibodies to myelin basic protein catalyze site-specific degradation of their antigen. Proc Natl Acad Sci USA 2006; 103:281-6; PMID:16387849; http://dx.doi. org/10.1073/pnas. 0509849103. (Pubitemid 43122392)
34. Brody DL, Holtzman DM. Active and passive immunotherapy for neurodegenerative disorders. Annu Rev Neurosci 2008; 31:175-93; PMID:18352830; http://dx.doi.org/10.1146/annurev.neuro.31.060407.125529.
35. Salloway S, Sperling R, Gilman S et al. A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. Neurology 2009; 73:2061-70; PMID:19923550; http://dx.doi.org/10.1212/ WNL.0b013e3181c67808.
36. Kasturirangan S, Boddapati S, Sierks MR. Engineered proteolytic nanobodies reduce Abeta burden and ameliorate Abeta-induced cytotoxicity. Biochemistry 2010; 49:4501-8; PMID:20429609; http://dx.doi. org/10.1021/ bi902030m.
37. Hifumi E, Morihara F, Hatiuchi K et al. Catalytic features and eradication ability of antibody light-chain UA15-L against Helicobacter pylori. J Biol Chem 2008; 283:899-907; PMID:17991752; http://dx.doi. org/10.1074/jbc.M705674200.
38. Nishiyama Y, Planque S, Mitsuda Y et al. Toward effective HIV vaccination: Induction of binary epitope reactive antibodies with broad HIV neutralizing activity. J Biol Chem 2009; 284:30627-42; PMID:19726674; http://dx.doi.org/10.1074/jbc.M109.032185.
39. Planque S, Mitsuda Y, Ghosh D et al. Prototype covalent HIV vaccine for inducing antibodies that neutralize genetically divergent virus strains. XVIII International AIDS Conference (AIDS 2010) 2010; Abstract: TUAA0101. http://pag.aids2010.org/flash/?pid=100572.
40. Vercruysse T, Pardon E, Vanstreels E et al. An intrabody based on a llama single-domain antibody targeting the N-terminal alphα-helical multimerization domain of HIV-1 rev prevents viral production. J Biol Chem 2010; 285:21768-80; PMID:20406803; http://dx.doi.org/10.1074/jbc.M110.112490.
41. Savarino A, Mai A, Norelli S et al. "Shock and kill" effects of class I-selective histone deacetylase inhibitors in combination with the glutathione synthesis inhibitor buthionine sulfoximine in cell line models for HIV-1 quiescence. Retrovirology 2009; 6:52; PMID:19486542; http://dx.doi.org/10. 1186/1742-4690-6-52.
42. Planque S, Taguchi H, Burr G et al. Broadly distributed chemical reactivity of natural antibodies expressed in coordination with specific antigen binding activity. J Biol Chem 2003; 278:20436-43; PMID:12668670; http://dx.doi.org/10.1074/jbc.M301468200. (Pubitemid 36799246)
43. Nishiyama Y, Mitsuda Y, Taguchi H et al. Towards covalent vaccination: Improved polyclonal HIV neutralizing antibody response induced by an electrophilic gp120 V3 peptide analog. J Biol Chem 2007; 282:31250-6; PMID:17728243; http://dx.doi.org/10.1074/jbc.M706471200. (Pubitemid 350044846)
44. Durova OM, Vorobiev II, Smirnov IV et al. Strategies for induction of catalytic antibodies toward HIV-1 glycoprotein gp120 in autoimmune prone mice. Mol Immunol 2009; 47:87-95; PMID:19201029; http:// dx.doi.org/10.1016/j.molimm. 2008.12.020.
45. Paul S, Sun M, Mody R et al. Peptidolytic monoclonal antibody elicited by a neuropeptide. J Biol Chem 1992; 267:13142-5; PMID:1377678.
46. Mirshahi M, Shamsipour F, Mirshahi T et al. A novel monoclonal antibody with catalytic activity against beta human chorionic gonadotropin. Immunol Lett 2006; 106:57-62; PMID:16759712; http://dx.doi. org/10.1016/j.imlet.2006.04.008. (Pubitemid 44109734)
47. Nishiyama Y, Karle S, Mitsuda Y et al. Towards irreversible HIV inactivation: Stable gp120 binding by nucleophilic antibodies. J Mol Recognit 2006; 19:423-31; PMID:16838382; http://dx.doi.org/10.1002/ jmr.795. (Pubitemid 44433821)